<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0163">For both HIV-1 and HBV infections, immunomodulatory therapies continue to be a balance between harnessing highly effective responses and limiting significant toxicities. Novel approaches to achieve these goals offer both the opportunity to move closer to a cure and the chance to define critical pathways that maintain chronic infection.</p>
